{
  "guideline": {
    "id": "PA166328741",
    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Indicate a Potential Impact on Safety or Response]: Simvastatin - SLCO1B1",
    "objCls": "PGx Association",
    "source": "FDA",
    "version": 0,
    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328741",
    "relatedChemicals": [
      {
        "id": "PA451363",
        "name": "simvastatin",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA134865839",
        "name": "solute carrier organic anion transporter family member 1B1",
        "symbol": "SLCO1B1"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166315422",
      "name": "Recommendation Annotation PA166315422",
      "population": "Affected subgroup: SLCO1B1 521 TC or 521 CC (intermediate or poor function transporters)",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451363",
          "name": "simvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452246341,
        "html": "<p>&quot;Results in higher systemic concentrations and higher adverse reaction risk (myopathy). The risk of adverse reaction (myopathy) is higher for patients on 80 mg than for those on lower doses.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "SLCO1B1": "Decreased Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166315423",
      "name": "Recommendation Annotation PA166315423",
      "population": "Affected subgroup: SLCO1B1 521 TC or 521 CC (intermediate or poor function transporters)",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451363",
          "name": "simvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452246342,
        "html": "<p>&quot;Results in higher systemic concentrations and higher adverse reaction risk (myopathy). The risk of adverse reaction (myopathy) is higher for patients on 80 mg than for those on lower doses.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "SLCO1B1": "Possible Decreased Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166315421",
      "name": "Recommendation Annotation PA166315421",
      "population": "Affected subgroup: SLCO1B1 521 TC or 521 CC (intermediate or poor function transporters)",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451363",
          "name": "simvastatin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452246340,
        "html": "<p>&quot;Results in higher systemic concentrations and higher adverse reaction risk (myopathy). The risk of adverse reaction (myopathy) is higher for patients on 80 mg than for those on lower doses.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "SLCO1B1": "Poor Function"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    }
  ],
  "citations": [],
  "version": "2024-03-08-14-34"
}